{"id":"https://openalex.org/W2189254682","doi":null,"title":"Re: Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Im- munotherapy in Metastatic Castration-Resistant Prostate Cancer","display_name":"Re: Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Im- munotherapy in Metastatic Castration-Resistant Prostate Cancer","publication_year":2010,"publication_date":"2010-01-01","ids":{"openalex":"https://openalex.org/W2189254682","mag":"2189254682"},"language":"en","primary_location":{"id":"mag:2189254682","doi":null,"is_oa":false,"landing_page_url":"https://www.europeanurology.com/article/S0302-2838(10)00552-X/pdf/re-overall-survival-analysis-of-a-phase-ii-randomized-controlled-trial-of-a-poxviral-based-psa-targeted-immunotherapy-in-metastatic-castration-resistant-prostate-cancer","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null},"volume":null,"type":"letter","indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5025426969","display_name":"Prasanna Sooriakumaran","orcid":"https://orcid.org/0000-0002-1398-3961","observed_orcids":["https://orcid.org/0000-0002-1398-3961"]},"institutions":[{"id":"https://openalex.org/I205783295","display_name":"Cornell University","ror":"https://ror.org/05bnh6r87","country_code":"US","type":"education","lineage":["https://openalex.org/I205783295"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Prasanna Sooriakumaran","raw_affiliation_strings":["cornell University"],"raw_orcid":"https://orcid.org/0000-0002-1398-3961","affiliations":[{"raw_affiliation_string":"cornell University","institution_ids":["https://openalex.org/I205783295"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068285584","display_name":"Ashutosh Kumar Tewari","orcid":"https://orcid.org/0000-0002-3146-4524","observed_orcids":["https://orcid.org/0000-0002-3146-4524"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ashutosh Tewari","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-3146-4524","affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5012881803","display_name":"Starr Pavilion","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Starr Pavilion","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10543","display_name":"Prostate Cancer Treatment and Research","score":0.9169999957084656,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10543","display_name":"Prostate Cancer Treatment and Research","score":0.9169999957084656,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.05829999968409538,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.0052999998442828655,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cancer-vaccines","display_name":"cancer vaccines","score":0.6019999980926514},{"id":"https://openalex.org/keywords/metastatic-castration-resistant-prostate-cancer","display_name":"metastatic castration-resistant prostate cancer","score":0.9620000123977661},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.8040000200271606},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.7070000171661377},{"id":"https://openalex.org/keywords/response-assessment-criteria","display_name":"response assessment criteria","score":0.6489999890327454},{"id":"https://openalex.org/keywords/sipuleucel-t","display_name":"sipuleucel-T","score":0.9520000219345093},{"id":"https://openalex.org/keywords/phase-ii-trial-design","display_name":"phase II trial design","score":0.5289999842643738}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8175615072250366},{"id":"https://openalex.org/C2780192828","wikidata":"https://www.wikidata.org/wiki/Q181257","display_name":"Prostate cancer","level":3,"score":0.8153135180473328},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6796087026596069},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.6748953461647034},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.6603955030441284},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5554981231689453},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.5315399169921875},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.5171439051628113},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.4901054799556732},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.4754773676395416},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3772287964820862}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:2189254682","doi":null,"is_oa":false,"landing_page_url":"https://www.europeanurology.com/article/S0302-2838(10)00552-X/pdf/re-overall-survival-analysis-of-a-phase-ii-randomized-controlled-trial-of-a-poxviral-based-psa-targeted-immunotherapy-in-metastatic-castration-resistant-prostate-cancer","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":1,"referenced_works":["https://openalex.org/W1988043237"],"related_works":["https://openalex.org/W2155846302","https://openalex.org/W4250744861","https://openalex.org/W2114156781","https://openalex.org/W2062605629","https://openalex.org/W1999518231","https://openalex.org/W2130227816","https://openalex.org/W2030203855","https://openalex.org/W1980370903","https://openalex.org/W1940135647","https://openalex.org/W2047910850"],"abstract_inverted_index":{"the":[0,8,20,32,85,100,103,110,122,127,138,143,148,154,176,190,227,267,275],"castration-resistant":[1],"setting":[2],"are":[3,198,214],"a":[4,40,55,218,221,230],"further":[5],"demonstration":[6],"of":[7,10,22,92,223,229],"promise":[9,77],"cancer":[11,160],"vaccines":[12],"in":[13,25,43,64,78,121,156],"this":[14,74],"setting,":[15],"while":[16,73],"also":[17],"pointing":[18],"to":[19,38,50,165,238,264],"possibility":[21],"their":[23],"use":[24],"patients":[26],"with":[27,54,66,163,170,178,200,220],"less":[28],"advanced":[29,44],"disease.":[30,71],"If":[31],"immune":[33,232],"system":[34],"can":[35,242],"be":[36,48,97,243,254],"stimulated":[37],"demonstrate":[39,153],"meaningful":[41],"effect":[42],"disease,":[45],"it":[46,181,204,252],"would":[47],"expected":[49],"have":[51],"increased":[52],"efficacy":[53],"smaller":[56],"tumor":[57,140],"burden":[58],"postprostatectomy":[59,65],"at":[60],"PSA":[61,124,128,136],"recurrence":[62],"or":[63,69,126,194],"patients\u2019":[67],"T3":[68],"margin-positive":[70],"However,":[72],"study":[75,111,150],"shows":[76],"demonstrating":[79],"an":[80],"overall":[81],"survival":[82],"advantage":[83],"between":[84,99,132],"vaccinated":[86],"and":[87,102,203],"nonvaccinated":[88],"groups,":[89,101,133],"no":[90,119],"evidence":[91],"specific":[93],"tumoral":[94],"effects":[95],"could":[96],"demonstrated":[98],"actual":[104],"PFS":[105],"end":[106,173,212],"point":[107],"on":[108,226,245],"which":[109],"was":[112,114,118,137],"designed":[113],"negative.":[115],"Indeed,":[116],"there":[117],"difference":[120],"serum":[123],"responses":[125,187],"antibody":[129],"titers":[130],"reported":[131],"despite":[134],"that":[135,185,234],"targeted":[139],"antigen.":[141],"Both":[142],"present":[144],"as":[145,147],"well":[146,183],"sipuleucel-T":[149],"and,":[151],"therefore,":[152],"challenge":[155],"clinically":[157],"developing":[158],"therapeutic":[159],"vaccines,":[161],"particularly":[162],"regard":[164],"designing":[166],"early":[167,210,271],"phase":[168,261,276],"studies":[169,263],"standard":[171],"clinical":[172],"points.":[174],"Unlike":[175],"case":[177],"cytotoxic":[179],"chemotherapy,":[180],"is":[182,205],"known":[184],"objective":[186],"defined":[188],"by":[189,195],"World":[191],"Health":[192],"Organization":[193],"RECIST":[196],"criteria":[197,249],"infrequent":[199],"immunotherapy":[201],"strategies,":[202],"not":[206],"clear":[207],"whether":[208],"even":[209],"progression-based":[211],"points":[213],"appropriate":[215],"for":[216,250,256,269],"evaluating":[217],"treatment":[219],"mechanism":[222],"action,":[224],"based":[225],"development":[228],"host":[231],"response,":[233],"may":[235],"take":[236],"months":[237],"develop.":[239],"Until":[240],"consensus":[241],"reached":[244],"valid":[246],"response":[247],"assessment":[248],"immunotherapies,":[251],"will":[253],"difficult":[255],"investigators":[257],"conducting":[258],"single":[259],"arm,":[260],"1/2":[262],"justify":[265],"expending":[266],"resources":[268],"taking":[270],"experimental":[272],"therapies":[273],"into":[274],"3":[277],"setting.":[278]},"counts_by_year":[],"updated_date":"2026-10-28T10:33:24.094632","created_date":"2016-06-24T00:00:00"}